The microbiota is now recognised as a key influence on the host immune response in the 2 central nervous system (CNS). As such, there has been some progress towards therapies 3 that modulate the microbiota with the aim of limiting immune-mediated demyelination, as 4 occurs in multiple sclerosis. However, remyelination -the regeneration of myelin sheaths -5 also depends upon an immune response, and the effects that such interventions might have 6 on remyelination have not yet been explored. Here, we show that the inflammatory 7 response during CNS remyelination in mice is modulated by antibiotic or probiotic 8 treatment, as well as in germ-free mice. We also explore the effect of these changes on 9 oligodendrocyte progenitor cell differentiation, which is inhibited by antibiotics but 10 unaffected by our other interventions. These results reveal that high combined doses of oral 11 antibiotics negatively influence remyelination and further our understanding of how 12 mammalian regeneration relates to the microbiota. 13
Introduction 1 Our knowledge of the microbiota and its relationship with host immunity, metabolism and 2 neurobiology has significantly expanded in recent years (1). However, the role of the 3 microbiota in mammalian regeneration remains relatively unexplored. As endogenous tissue 4 regeneration is facilitated by a local immune response (2), it is feasible that intestinal 5 microbes, which modulate the host immune system (3, 4) , could help shape the outcome of 6 regeneration in a clinical setting. The gut microbial community can be easily modified using 7 oral antibiotics or probiotics, thus addressing this question is of great clinical relevance. 8 9 Here, we investigate how the intestinal microbiota influences remyelination, the most 10 effective form of regeneration observed in the mammalian central nervous system (CNS) and 11 a promising therapeutic strategy for multiple sclerosis (MS) and other myelin diseases (5) . 12
Successful remyelination can bring functional recovery (6,7) and protect axons from 13 degeneration (8) . This success depends on an inflammatory response by microglia and 14 infiltrating macrophages (9) that progresses and resolves appropriately (10,11). Due to its 15 distance from any epithelial interface with environmental microbes, CNS remyelination is an 16 ideal model to explore systemic influences of the microbiota on regeneration. 17 18 The rationale for our studies is based on the close relationship between remyelination and 19 the innate immune response, and in turn between the immune system and the microbiota. 20
To create an environment that permits remyelination, endogenous microglia and infiltrating 21 macrophages must clear myelin debris remaining from the disintegrated sheath (12), and also 22 secrete pro-regenerative factors (10,11,13). These roles hinge upon a coordinated immune 23 response to demyelination, failure of which can impair remyelination, as occurs in older 24 animals (14, 15) . Meanwhile, there is now a substantial body of evidence linking the 25 microbiota to CNS inflammation across various contexts. For example, germ-free or 26 antibiotics-treated mice have transcriptionally immature microglia, which have an impaired 27 response to lipopolysaccharide (LPS) or viral stimulation (3), whilst antibiotic depletion of the 28 microbiota reduces monocyte entry into the brain (4). The immune system is therefore a 29 strong candidate for conveying an influence from the microbiota to regeneration in distant 30 tissues such as the CNS. 31 (4), which we confirmed by quantitative RT-PCR of faecal DNA (Fig. 1B) . Demyelination was 23 then induced by focal injection of lysolecithin into the ventral white matter of the spinal cord. To investigate baseline differences in microglia following ABX treatment, areas of unlesioned 1 white matter were stained with an antibody to Iba1. Microglial morphology, which correlates 2 with activity within a given tissue (3, 23) , was then analysed ( Fig. 1 supplement 1A) . Whilst a 3 principal component analysis based on a number of morphological features showed clear 4 separation between microglia from grey and white matter, there were no differences 5 detected in microglia of unlesioned white matter following ABX treatment ( Fig. 1 supplement  6   1B) . 7 8 The inflammatory response within lesions was examined at 7 and 14 days post lesion (dpl) by 9 staining for CD68 to label activated microglia and infiltrating macrophages. As subpopulations 10 of microglia/macrophages have distinct effects in remyelination (11), we also quantified 11 several markers expressed by subpopulations of these CD68+ cells. This panel consisted of 12 two M1-associated markers (major histocompatibility complex class II (MHCII) and inducible 13 nitric oxide synthase (iNOS)) and two M2-associated markers (arginase-1 (Arg1) and mannose 14 receptor (MR)) (11,24). 15 16 At 7 dpl, lesions of ABX-treated mice were the same size as specific pathogen-free (SPF) 17 controls (Fig 1 supplement 1C) and with the same total density of CD68+ 18 microglia/macrophages (Fig. 1C,D) . However, there were fewer CD68+ cells expressing either 19 MHCII ( Fig. 1E,F) or Arg1 ( Fig. 1G,H) . To determine the reversibility of this effect, ABX-treated 20 mice received a faecal microbial transplant (FMT) from SPF mice by oral gavage to 21 reconstitute their microbiota. With FMT treatment, Arg1 expression increased and was no 22 longer significantly different from SPF control levels ( Fig. 1H) , whereas MHCII expression 23 remained low (Fig. 1F) . The other two other markers investigated (iNOS and MR) were not 24 altered following ABX treatment ( Fig. 1 supplement 1D-G) . At a later timepoint, 14dpl, 25 differences were no longer observed in either Arg1 or MHCII in the ABX-treated mice ( Fig. 1E -26 H). However, the total number of CD68+ microglia/macrophages was increased following ABX 27 treatment and not reversed by FMT (Fig. 1C,D) . 28 29 Taken together, these results indicate that broad-spectrum antibiotic treatment results in 30 dysregulated CNS inflammation following demyelination. Specifically, we observed an 31 increase in total CD68+ cells from 7 to 14dpl in ABX-treated groups, not seen amongst SPF 32 7 controls. Coupled with this, MHCII and Arg1 expression by microglia/macrophages in the ABX-1 treated groups were initially low, catching up to control levels with the increase in total CD68+ 2 cells at 14dpl. Whilst microglia/macrophages expressing M1-or M2-associated markers are 3 considered to have distinct functional effects during remyelination (11), we did not observe 4 concomitant regulation of either M1-or M2-associated markers with our interventions, 5 highlighting the intricacies of CNS inflammation in this context. Instead, our microbial 6 depletion model was dominated by a delayed but aggressive pro-inflammatory innate 7 immune response. 8
9
Combined antibiotics treatment impairs myelin debris clearance and OPC 10 differentiation 11 Central to CNS remyelination is the generation of new oligodendrocytes to restore the myelin 12 sheath. These derive from endogenous OPCs, which migrate to lesions, proliferate and 13 subsequently differentiate into oligodendrocytes (5, 25) . Defective differentiation from OPC 14 to oligodendrocyte is commonly the bottleneck at which remyelination fails in human lesions 15 and animal models (26-28). Microglia and infiltrating macrophages promote remyelination 16 through the clearance of myelin debris, which blocks OPC differentiation in culture (29) and 17 impairs remyelination in demyelinated lesions (12). We investigated whether the 18 dysregulated inflammatory response following ABX treatment would be associated with 19 reduced myelin debris clearance. 20 21 Lesions were stained with an antibody for a degraded epitope of myelin basic protein (dMBP), 22 which becomes exposed in myelin debris (30) ( Fig. 2A,B) . At 7dpl, antibiotics did not affect 23 the quantity of myelin debris in the lesion area. By 14dpl there had been an expected 24 reduction in myelin debris in the SPF controls: however, this was less pronounced amongst 25 the ABX-treated group, with more debris persisting at the later timepoint. The effect was 26 reversed in the FMT group, which had a similar dMBP+ area to controls. 27
28
We next explored how the OPC response would be affected by ABX treatment, using the 29 nuclear transcription factor Olig2 to label cells of the oligodendrocyte lineage and CC1 to 9 distinguish differentiated oligodendrocytes (CC1+) from OPCs (CC1-). ABX did not affect the 1 total number of OPCs present ( Fig. 2D,E) , nor the number of proliferating OPCs identified 2 by Ki67 staining (Fig. 2C,F) . However, there were fewer differentiated oligodendrocytes in 3 the lesions of ABX-treated mice at 14dpl, suggesting a defect in OPC differentiation ( Fig.  4 2D,G). This was not restored by FMT in the ABX-treated group. 5 6 In summary, following demyelination in ABX-treated mice, the altered inflammatory 7 response is associated with impaired myelin debris clearance and impaired OPC 8 differentiation. The effects of ABX treatment on remyelinating lesions could feasibly be 9 caused by either ABX-mediated depletion of the microbiota or other off-target effects of 10 this oral ABX regime. Two approaches were taken to explore these possibilities: 1) testing 11 for off-target effects of ABX on relevant CNS cells in culture and 2) investigating 12 remyelination in germ-free (GF) mice, which were reared in a sterile environment and thus 13 were constitutionally devoid of microbes without ABX exposure. 14
15
Combined antibiotics treatment does not affect microglial phagocytosis or OPC 16 differentiation in vitro 17 Some antibiotics are able to penetrate and act directly within the CNS. One example is the 18 broad-spectrum tetracycline, minocycline, which can directly inhibit microglia and influence 19 remyelination (31) (32) (33) . Four of the antibiotics we administered were considered to have 20 sufficient bioavailability to reach the CNS in significant concentrations: ampicillin, 21 ciprofloxacin, metronidazole and the β-lactamase inhibitor sulbactam. Available 22 pharmacokinetic data (34-41) were used to estimate the concentrations these drugs would 23 reach in the murine CNS ( Fig. 3 supplement 1A) , which were then applied to primary murine 24 microglial cultures for 48 hours (Fig. 3A) . Following ABX treatment, microglia were exposed 25 to myelin debris and phagocytic uptake was quantified after 4 hours. None of the ABX 26 individually, nor in combination, directly inhibited myelin phagocytosis by microglia ( (A) Primary microglia were isolated from P6-8 mice using magnetic-activated cell sorting (MACS) for CD11b and cultured for 48 hours in the presence of antibiotics. Cells were fixed after exposure to myelin debris for 4 hours.
(B) After fixation, cells were stained with an antibody to MBP to visualise myelin uptake by phagocytosis.
(C) Myelin uptake following exposure to combined antibiotics at their estimated CNS concentration (++) or a 10% dose (+) was comparable to control levels.
(D) Primary OPCs were isolated from P6-8 mice using MACS for A2B5 and cultured in the presence of growth factors. After 4 days, antibiotics were applied and growth factors were withdrawn to allow differentiation. Cells were fixed after 6 days of differentiation, following 3 hours of EdU exposure.
(E) After fixation, cells were stained with an antibody to Olig2 and incorporated EdU was labelled to visualise OPC proliferation. 
11
ABX and the effects on differentiation and proliferation were determined by 1 immunocytochemistry after six days of differentiation conditions ( Fig. 3D-H) . ABX treatment 2 had no effect on OPC proliferation as measured by EdU ( Fig. 3E-F) , nor was there a 3 difference in expression of the differentiation marker CNPase ( Fig. 3G-H) . Similarly, applying 4 each antibiotic alone had no effect on these parameters (Fig 3 supplement 1C-D) . 5 6 Germ-free mice have a deficient inflammatory response during remyelination 7
The results from cell culture systems suggest that the deficits observed in ABX-treated mice 8 are not caused by direct effects of antibiotics on microglial or OPC functions critical for 9 remyelination. However, antibiotics may have other indirect effects that are difficult to 10 capture in vitro. To determine whether the microbiota can influence remyelination in the 11 absence of ABX exposure, we investigated how remyelination would proceed in germ-free 12 (GF) mice. As surgical lesions are impractical under the constraints of GF husbandry, we 13 employed the cuprizone model, in which demyelination is induced by dietary administration 14 of 0.2% cuprizone over a period of 5 weeks (Fig. 4A) . The sterility of the GF mice was 15 confirmed by faecal PCR for bacterial DNA (Fig. 4B ) as well as routine in-house screening of 16 animals and isolators using aerobic and anaerobic culture methods and microscopy of faecal 17
smears. An ex-GF group were colonised with a microbiota after weaning, by co-housing with 18 SPF controls, and this allowed us to distinguish developmental effects of lacking a 19 microbiota from those reversible in adulthood. After cuprizone exposure, all mice were 20 returned to a normal diet for a 3-week period of remyelination. 21
22
Like ABX-treated animals, GF mice had deficits in the inflammatory response that 23 accompanied demyelination. The total number of CD68+ activated microglia and 24 monocyte-derived macrophages was reduced in the GF group after the 5-week cuprizone 25 treatment and remained so 3 weeks after cuprizone was withdrawn ( Fig. 4C,D) . Numbers 26 of CD68+ cells were comparable to SPF controls in the ex-GF group, demonstrating that 27 colonisation of GF mice can restore immune responsiveness and delineates an ongoing, 28 dynamic role of the microbiota in the inflammatory response to tissue damage, rather 29 than a critical window during development. (A) Schematic diagram of the GF experiment: GF mice and SPF controls were fed a diet containing 0.2% cuprizone for 5 weeks from 8 weeks of age. Mice were sacrificed at the end of cuprizone administration, or after 3 weeks return to normal diet. A third group consisted of GF mice that were co-housed with SPF mice from 4 weeks of age, becoming colonised with a microbiota after weaning.
(B) PCR for a universal prokaryotic 16S sequence in faecal DNA demonstrating absence of this amplicon in GF mice and its presence in the ex-GF group.
(C-D) Representative images (C) and density (D) of CD68+ activated microglia / infiltrating macrophages within the corpus callosum (yellow line) in cuprizone naïve mice, following 5 weeks cuprizone exposure (5w) and following a further 3 weeks of normal diet (5+3w). 
13
To investigate this inflammatory response in more detail, we stained for the same panel of 1 microglia/macrophage markers as tested in the antibiotics experiment. Previously, ABX-2 treated mice were both found to have reduced expression of both MHCII and Arg1 during 3 remyelination ( Fig. 1E-H) . Here, MHCII was similarly diminished in the remyelinating 4 corpus callosum of GF mice, with negligible expression in microglia of any of these animals 5 ( Fig. 4E,F) . There was no significant reduction in Arg1, despite a similar trend ( Fig. 4G,H) , 6 nor was there a difference detected in iNOS or MR expression in GF mice (Fig 4  7 supplement 1A-D). A caveat for these negative results is that our study was powered to 8 detect differences in OPC responses, and we observed considerable variability in the 9 inflammatory responses between animals. 10 11
The deficits in the immune response of ABX-treated mice were associated with reduced 12 myelin debris clearance after demyelination ( Fig. 2A,B ). A timecourse of cuprizone feeding 13 in SPF mice showed that extensive dMBP+ myelin debris after 3 weeks of cuprizone diet is 14 subsequently cleared by 5 weeks (Fig 4 supplement 1E) . We subsequently compared dMBP 15 staining at our 5w timepoint to determine whether myelin debris clearance was impaired 16 under GF conditions. All groups showed similarly low levels of dMBP staining at 5w, 17
indicating that any delay in debris clearance was not persistent beyond 5 weeks (Fig 4  18 
supplement 1E,F). 19 20
In summary, we observed that the initial inflammatory response following demyelination in 21 GF mice was altered in a similar pattern to ABX-treated animals, namely reduced numbers 22 of CD68+ microglia/infiltrating macrophages with a corresponding reduction in MHCII 23 expression. These changes point towards the microbiota being an important regulator of 24 the immune response in the CNS during demyelination and remyelination. However, in our 25 cuprizone model, the altered inflammatory response was not associated with a delay in 26 myelin debris clearance after 5 weeks. 27
28
Germ-free mice have normal OPC differentiation during remyelination 29 Next, the OPC responses during cuprizone-mediated demyelination and remyelination were 30 examined in GF mice. Prior to cuprizone exposure, GF and SPF mice had comparable 31 numbers of Olig2+CC1-OPCs ( Fig. 5A,B ) and Olig2+CC1+ oligodendrocytes ( Fig. 5A,C) in the 1 corpus callosum. Following 5 weeks cuprizone treatment, there was an 80% reduction in 2 the density of Olig2+CC1+ oligodendrocytes in the SPF group (Fig. 5C) . In contrast, the loss 3 of oligodendrocytes after 5 weeks of cuprizone was less extensive amongst the GF group, 4 whilst the ex-GF group were in line with SPF controls. At this timepoint, all groups 5 experienced a similar rise in Olig2+CC1-OPCs ( Fig. 5B) , consistent with the phase of OPC 6 migration and proliferation known to occur during the first 5 weeks of cuprizone 7 administration (42). However, when we specifically quantified Olig2+Ki67+ proliferative 8
OPCs at 5 weeks, this was higher in the GF mice than the other two groups (Fig. 5D,E) . 9 10 Three weeks after cuprizone withdrawal, a timepoint at which remyelination should be 11 progressing (42,43), all three groups exhibited a fall in OPC counts with a concurrent rise in 12 differentiated oligodendrocytes. Importantly, there were no differences in OPC or 13 oligodendrocyte numbers between the groups at this later timepoint ( Fig. 5B,C ), suggesting 14 that there was no delay in OPC differentiation during the remyelination of GF mice. 15 16 Finally, the degree of remyelination following cuprizone cessation was investigated by 17 transmission electron microscopy (Fig. 5F) . The corpus callosum of SPF controls, GF and ex-18 GF mice all exhibited comparable densities of myelinated axons 3 weeks after cuprizone 19 treatment was stopped, indicating that remyelination had progressed similarly between 20 groups (Fig. 5G) . The g-ratios of these axons were also measured and likewise revealed no 21 differences (Fig 5 supplement 1A,B ). 22
23
In summary, GF mice were partially resistant to the effects of cuprizone, with less extensive 24 oligodendrocyte loss following 5 weeks of dietary administration. This effect could be 25 related to their diminished innate immune response during cuprizone treatment ( Fig. 4) , 26
given that various studies have demonstrated a role of the immune system, particularly 27 microglia and neutrophils, in mediating cuprizone-induced demyelination (44,45). The late 28 peak in OPC proliferation observed in the GF group (Fig. 5D,E) , may similarly be in response 29 to a sluggish innate immune response. However, 3 weeks after cuprizone was stopped, the 30 absence of any difference in OPC or oligodendrocyte numbers combined with similar 31 densities of myelinated axons suggest that remyelination itself is unaffected in GF mice. Probiotic VSL#3 can augment the innate immune response during CNS remyelination 1 Taking the results from the antibiotics and germ-free experiments, together with in vitro 2 studies, an intact microbiota appears to be necessary for the appropriate inflammatory 3 response during remyelination. However, the effect that microbial depletion has on OPC 4 responses, and thus remyelination itself, remains less certain. We next explored the inverse 5 of this relationship: whether the microbiota can be manipulated therapeutically to enhance 6 appropriate inflammatory responses and subsequently remyelination. For this, we used 7 older mice (aged 14 months) in which remyelination occurs more slowly with scope for 8 improvement (14, 46) . For this study, mice were administered the probiotic VSL#3 by daily 9 gavage for 1 month, prior to inducing focal demyelination in the spinal cord white matter 10 by lysolecithin injection (Fig. 6A) . 11 12 VSL#3, a freeze-dried formulation of 8 strains of Gram-positive bacteria ( Fig. 6B) , was 13 chosen due to its good survival on transit through the GI tract (47) and several characterised 14 therapeutic effects in the CNS (4,48,49). Additionally, VSL#3 enhanced concentrations of 15 short chains fatty acids (SCFAs) in the faeces and serum of mice ( Fig. 6 supplement 1B,D) , 16 consistent with a previous study (50). The SCFAs acetate, butyrate and propionate are 17 microbial metabolites that are depleted in GF mice ( Fig. 6 supplement 1A ,C) and considered 18 key signalling molecules in how the microbiota influence CNS inflammation (3, 51) . 19 20 Following VSL#3 treatment, there was a mild enhancement in the inflammatory response 21 at 5dpl, with greater density of CD68+ activated microglia and infiltrating macrophages ( Fig.  22 6C,D). When more specific inflammatory markers were quantified, both iNOS and MR were 23 expressed by greater numbers of microglia/macrophages in lesions following probiotic 24 treatment at 5dpl ( Fig. 6E-H) . No differences were detected at 14dpl, a timepoint at which 25 debris should be largely cleared and newly differentiated oligodendrocytes initiate 26 remyelination. This shows that although probiotics augmented the initial inflammatory 27 response at 5dpl, this was not sustained, detrimental inflammation. It was noted that 28 expression of the two markers initially reduced by ABX (MHCII and Arg1) were not 29 significantly enhanced by probiotic treatment (Fig. 6 supplement 1E-H VSL#3 does not improve the outcome of remyelination 1 Finally, we assessed whether this inflammatory enhancement during the early stages would 2 contribute to a better outcome in remyelination. In contrast to ABX-treated mice, in which 3 the reduced inflammatory response resulted in prolonged presence of myelin debris, myelin 4 debris was not cleared any faster in the lesions of probiotic-treated mice (Fig. 7A,B) . 5
Consistent with this, there was no difference in the OPC response, with OPC number (Fig.  6 7C,D), proliferation ( Fig. 7 supplement 1A-B ) and differentiation of new oligodendrocytes 7 at 14dpl (Fig. 7C,E) unchanged by probiotic treatment. There was a small increase in the 8 number of oligodendrocytes present at 5dpl (Fig. 7C,E) . As this timepoint is considered too 9 early for significant OPC differentiation to occur, even in young adults (52) and taking to 10 account that no difference was observed at 14dpl, the peak time for OPC differentiation, 11 this likely reflects a reduction in oligodendrocyte death, rather than enhanced OPC 12 differentiation. 13
14
To confirm that there was no therapeutic effect of VSL#3 on remyelination, semi-thin resin 15 sections were taken at a later timepoint (21dpl) and myelin stained with toluidine-blue ( Fig.  16   7F) . The completion of remyelination was ranked by two blind assessors, neither of whom 17 detected a difference in remyelination between groups (Fig. 7G) . 18
19
Thus, administration of the probiotic VSL#3 promoted a stronger initial inflammatory 20 response in aged mice following demyelination. However, this did not lead to faster 21 clearance of myelin debris or OPC differentiation, and overall remyelination was unchanged 22 compared to control mice. The aim of these experiments was to explore how the microbiota can influence 2 remyelination in the mammalian CNS. Across all three models, the responses of microglia 3 and infiltrating macrophages were modulated by interventions that altered the microbiota. 4
Broadly, this amounted to a blunting of the early immune response in ABX-treated or GF 5 mice and an enhancement in the onset of inflammation when treated with the probiotic 6 VSL#3. Alongside this, ABX-treated mice had deficits in myelin debris clearance and OPC 7 differentiation. However, these findings were neither replicated in GF mice, nor reversed 8 by probiotic administration. In vitro, ABX did not directly influence microglial phagocytosis 9 or OPC proliferation and differentiation, though other indirect effects of ABX are difficult to 10 exclude. Bringing together these findings from different models, the microbiota consistently 11 shapes the inflammatory response during CNS remyelination, but the effect of this on 12 regenerative responses by OPCs is limited. it seems likely that such interactions become less relevant at anatomically distant sites -for 20 example, the evidence linking liver regeneration to the microbiota is more contentious 21 (56,57). Outside a regenerative context, changes in developmental or adaptive myelination 22 in the CNS have previously been linked to the microbiota. GF mice are hypermyelinated 23 specifically in the prefrontal cortex (PFC) (58), whilst a PFC hypomyelination phenotype 24 could be transferred between different strains of mice by FMT (59). Whilst a role for the 25 microbiota in myelin homeostasis is exciting, the findings of both studies were region-26 specific and occur in a very different context to remyelination, which is accompanied by 27 tissue damage and a robust inflammatory response that directly influences the efficiency of Cuprizone administration to germ-free mice. 21
Male C57BL/6 mice were bred from a GF nucleus colony at the University of East Anglia and 22 maintained in a flexible-film isolator, supplied with sterilised air, food, water and bedding. 23
The GF group were maintained in these conditions throughout the experiment and 24 compared to aged-matched SPF controls. The ex-GF mice were littermates of the GF group 25 and remained in GF conditions until after weaning (4 weeks old), at which point they 26 acquired a microbiome by co-housing with the SPF mice. Animals and isolators were 27 monitored by routine in-house screening using aerobic and anaerobic culture methods, as 28 well as microscopy of faecal smears. Demyelination was initiated by administration of a 29 0.2% cuprizone diet (TD.140803, Envigo, Huntingdon, UK), which received 50kGy γ-30 irradiation for sterilisation. All groups received the cuprizone diet for 5 weeks beginning at 31 age 2 months in place of their regular diet and were then returned to regular diet for 3 32 23 weeks afterwards. Cuprizone diet was stored sealed at 4°C and replaced every 2-3 days 1 during administration. During the 5-weeks of cuprizone diet, mice were regularly weighed 2 and if substantial weight loss occurred (>15%), the diet was supplemented with small 3 quantities of normal chow, given equally across all three groups. Mice were perfused with 4 in the same manner as the antibiotics study either before the initiation of cuprizone (naïve), 5 after 5 weeks cuprizone diet (5w) or after a subsequent 3 weeks of normal diet (5+3w). The 6 brain was retrieved and bisected sagittally, with the left hemisphere post-fixed in PFA for 7 immunohistochemistry (IHC) and the right hemisphere post-fixed in 4% glutaraldehyde for 8 electron microscopy analysis. For IHC, 20μm coronal sections of the left hemisphere were 9 taken from bregma -1 to 1mm. 10 11 Focal lysolecithin lesions in probiotic-treated mice. 12 13-month old female C57BL/6 mice were administered a daily dose of 1.35x10 9 colony 13 forming units of VSL#3 (a gift from Janine DeBeer, Ferring Pharmaceuticals, London, UK), 14 suspended in 100μl autoclaved water by oral gavage for 28 days. These were compared to 15 age-matched control mice, which were instead gavaged daily with 100μl water. Randomly 16 allocated control and probiotic-treated mice were housed in separate racks necessitating a 17 change of gloves between handling, to avoid cross-contamination. Following this treatment, 18 all groups received a focal injection of lysolecithin as described in the antibiotics study. 19
Gavage treatments were recommenced from two days after this surgery and mice were 20 sacrificed by perfusion-fixation at 5 or 14 dpl with 4% PFA or at 21 dpl with 4% 21 glutaraldehyde. Microglia were isolated from P6-8 C57BL/6 mouse pups using a Magnetic-Activated Cell 8
Sorting (MACS) protocol (Fig. 3A) . Pups were euthanised by overdose of Pentoject 9 (Animalcare Ltd., Hull, UK) and brains from 2-3 pups were pooled per replicate. Tissue was 10 diced into small pieces and incubated at 37°C for 30 minutes in a dissociation solution, 11 consisting of 34 U/ml papain (Worthington, Lakewood, NJ) and 20 μg/ml DNAse (Gibco, 12 Thermo Fisher Scientific) in HALF (Hibernate-A equivalent, made in house). After this, tissue 13 was triturated with a fire-polished glass pipette, passed through a 70μm cell strainer 14 500μM N-acetylcysteine and 1% penicillin-streptomycin. After 48 hours, media was 21 changed to macrophage serum-free medium (Thermo Fisher Scientific), containing the 22 antibiotic treatments. Following a further 48 hours, 10μg/ml myelin debris was added to 23 each well for 4 hours. Myelin debris had been isolated from 2-3 month old C57BL/6 mice by 24 discontinuous sucrose gradient centrifugation, as previously described (12, 15) . After this 25 incubation, un-internalised debris was removed by washing with cold PBS and cells were 26 fixed with 4% PFA. 27
28

OPC isolation and culture 29
OPCs were isolated from P6-8 C57BL/6 mouse pups using a MACS protocol (Fig. 3D) , which 30 was identical to the microglia protocol until the labelling stage. Cells were instead incubated 31 with 1:1000 anti-A2B5 (Millipore) and then a magnetic bead-coupled goat-anti-mouse-IgM 1 antibody (Miltenyi Biotech), prior to MACS. A2B5+ OPCs were cultured at 5000 cells per well 2 of a poly-D-lysine and laminin-coated 96-well microplate, in DMEM/F12 (Gibco)  3 supplemented with 5μg/ml insulin (Gibco), 1x Trace Elements B (Corning), 100μg/ml apo-4 transferrin, 16.1μg/ml putrescine, 40ng/ml sodium selenite, 60ng/ml progesterone, 5 60μg/ml N-acetylcysteine and 1% penicillin-streptomycin, 5μM forskolin and 1ng/ml biotin 6 (all Sigma-Aldrich unless otherwise indicated). Cultures received growth factors for the first 7 4 days (10ng/ml/day of platelet-derived growth factor α (PDGFα) and fibroblast growth 8 factor 2 (FGF2)), after which antibiotic treatments were introduced for a further six days 9 (replaced after 3 days) in the absence of growth factors to allow differentiation. Cells were 10 then incubated with 10μM 5-ethynyl-2'-deoxyuridine (EdU) for 3 hours prior to fixation with 11 4% PFA. 12 13
Antibiotic treatments in vitro 14
To apply antibiotic treatments (all Sigma-Aldrich) at doses approximating those of in vivo 15 exposure, steady state plasma concentrations (CSS(P)) were estimated for each antibiotic 16 administered to mice in their drinking water ( Fig. 3 supplement 1A) . These estimations were 17 based on literature values of oral bioavailability (F), clearance (CL), and area-under-the-18 curve ratio of cerebrospinal fluid (CSF) to plasma (AUCCSF/AUCP), for ampicillin and 19 sulbactam (34-36), ciprofloxacin (37-39) and metronidazole (39) (40) (41) . Daily water 20 consumption was assumed to be 4 ml/day/mouse. 21
22
Immunocytochemistry 23
Fixed cells in 96-well plates were blocked for 1 hour with 5% NDS and 0.1% triton in PBS. 24
For the cell proliferation assay, EdU was labelled at this point using the Click-iT EdU Alexa 25
Fluor 647 Imaging Kit (Thermo Fisher Scientific). Cells were then incubated with primary 26 antibodies diluted in blocking solution overnight at 4°C. Primary antibodies: mouse anti-27
CD11b 1:300 (MCA275R, Serotec), mouse anti-CNPase 1:500 (C5922, Sigma-Aldrich), rat 28 anti-MBP 1:500 (MCA409S, Serotec), rabbit anti-Olig2 1:500 (AB9610, Millipore). Cells were 29 then washed three times with PBS and incubated with relevant fluorophore-conjugated 30 secondary antibodies (see "Immunohistochemistry") diluted in blocking solution for 1 hour 31 at RT and protected from light. Nucleic acids were stained by 10 minutes incubation with 32 1μg/ml Hoechst, followed by three more PBS washes. Images were acquired automatically 1 using an InCell2200 (GE Healthcare, Chicago, IL) or a Cell Insight CX5 (Thermo Fisher 2 Scientific). The blood samples were incubated in sterile Eppendorf tubes for 1 hour at RT to allow 23 coagulation, then separated by centrifugation for 15 minutes at 1500g. Serum was collected 24 and stored at -80°C. 25 26 Short chain fatty acids (SCFAs) were extracted using a modified Bligh and Dyer method (66). 27
In short, 15-25mg of faeces or 20µl of serum was transferred to a pre-chilled plastic tube 28 and extracted with ice-cold 2:2:1 methanol:chloroform:water containing internal standard, 29 following vigorous mixing, sonication and centrifugation (16,000g, 20 minutes). For serum 30 samples, 100µl of the aqueous phase was transferred to pre-chilled glass tubes. Faecal 31 samples were extracted twice, and a combined total of 300µl aqueous phase was 1 transferred to pre-chilled glass tubes. Aqueous phases were dried down under nitrogen at 2 4°C, and derivatised as described previously (67). 3 4 SCFAs were measured by gas chromatography-mass spectrometry (GC-MS), on a Trace GC 5
Ultra coupled to a Trace DSQ II mass spectrometer (Thermo Fisher Scientific). Derivatised 6 samples were diluted 1:1 with hexane, and 2µl was injected onto a 50m x 0.25mm (5% 7 phenyl-arylene, 95% dimethylsiloxane) column with a 0.25µm ZB-5MS stationary phase 8 (Phenomenex, Macclesfield, UK). Full-scan spectra were collected at three scans per second 9 over a range of 50 to 650 m/z. Data processing was carried out using Xcalibur (version 2.2, 10 Thermo Fisher Scientific), and peaks were assigned based on the National Institute of 11
Standards and Technology (USA) library. All solvents were of HPLC-grade or higher. lysolecithin study: n = 3-5 mice. These group sizes were chosen based on previous work and 20 were thought to be sufficiently powered to detect meaningful differences in the OPC / 21 inflammatory response to demyelination. For in vivo cell counts, generally 3 unusual myelin basic protein epitope during the process of myelin degeneration in 4 humans: a potential mechanism for the generation of autoantigens. Am J Pathol. 
